Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1104830

	registered interest
	date	25/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many people have been diagnosed with Ehlers-Danlos syndrome in each of the last five years.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	236425
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>To facilitate better and quicker diagnosis, patients with suspected Ehlers-Danlos syndrome (EDS) are eligible to be tested on the newly-established Genomic Medicine Service.</p><p> </p><p>NHS England commissions services for patients who have EDS from specialist rheumatology centres. Some patients may also be seen in more local services, commissioned by clinical commissioning groups, including rheumatology, physiotherapy, and dermatology. NHS England also commissions a Complex EDS service through two expert centres that ensures accurate diagnosis for patients where this has been difficult. The Complex EDS service provides management plans for local care providers and communicates which allows the local health care professionals to implement the recommendations and monitor the patient’s progress.</p><p> </p><p>We currently do not hold figures on the number of EDS diagnosis made in each of the last five years. However, Public Health England’s National Congenital Anomaly and Rare Disease Registration Service have been working to develop a rare disease registry which will collect prospective data on EDS diagnosis in England.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236424 236426 question first answered 02/04/2019 13:58:11 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4432 label Biography information for Patrick Grady

1104831

	registered interest
	date	25/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pregnancy: Hypermobility
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of testing expectant mothers for hypermobility.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	236426
	answer	answer is ministerial correction date of answer 02/04/2019 answer text <p>To facilitate better and quicker diagnosis, patients with suspected Ehlers-Danlos syndrome (EDS) are eligible to be tested on the newly-established Genomic Medicine Service.</p><p> </p><p>NHS England commissions services for patients who have EDS from specialist rheumatology centres. Some patients may also be seen in more local services, commissioned by clinical commissioning groups, including rheumatology, physiotherapy, and dermatology. NHS England also commissions a Complex EDS service through two expert centres that ensures accurate diagnosis for patients where this has been difficult. The Complex EDS service provides management plans for local care providers and communicates which allows the local health care professionals to implement the recommendations and monitor the patient’s progress.</p><p> </p><p>We currently do not hold figures on the number of EDS diagnosis made in each of the last five years. However, Public Health England’s National Congenital Anomaly and Rare Disease Registration Service have been working to develop a rare disease registry which will collect prospective data on EDS diagnosis in England.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 236424 236425 question first answered 02/04/2019 13:58:11 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4432 label Biography information for Patrick Grady

1108708

	registered interest
	date	01/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health and Care Professions Council: Fees and Charges
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish a response to Early Day Motion 2069 entitled Registration Fees at the Health and Care Professions Council.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	239265
	answer	answer is ministerial correction date of answer 04/04/2019 answer text <p>The Health and Care Professions Council (HCPC) is independent from Government and is funded by registrants’ fees on a cost recovery basis. Fees are set at an appropriate level to cover the cost of regulation.</p><p> </p><p>The Government has no plans at this time to publish any further response relating to the HCPC’s proposed fee rise.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 04/04/2019 12:27:11 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4432 label Biography information for Patrick Grady

1109775

	registered interest
	date	04/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will issue a response to Early Day Motion 1832, on legalisation of medical cannabis.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	241057
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>The Government is clear that the decision to prescribe a cannabis-based product for medicinal use should only be made where it is clinically appropriate and in the best interest of the patient. This will be subject to local National Health Service governance and funding arrangements for prescribing unlicensed medicines, and patients will not be able to be prescribed such products by their general practitioner – and would require referral to a specialist clinician on the basis of clinical need.</p><p>The evidence base for cannabis-based products for medicinal use is still developing. However, the changes to the law are designed to encourage further research and the National Institute for Health Research has issued two calls for research proposals to rapidly advance knowledge in this area and remains open to research proposals outside of these calls in this priority area.</p><p>Interim clinical guidance, issued by the Royal College of Physicians, British Paediatric Neurology Association and Association of British Neurologists is based on the best available international evidence and reflects clinical guidance that has been published in other jurisdictions. This guidance will be updated and replaced in October 2019 by that commissioned from the National Institute for Health and Care Excellence.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 09/04/2019 14:40:03 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4432 label Biography information for Patrick Grady

1122082

	registered interest
	date	18/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the answer of 1 April 2019 to Question 237706 on Epilepsy: Drugs, and with reference to the publication entitled, Epilepsy Society Calls For Urgent Review Of Medicines Supply Chain, published by the Epilepsy Society on 8 April 2019, if he will make an assessment of trends in the level of people with epilepsy that are unable to obtain epilepsy medication.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	245842
	answer	answer is ministerial correction date of answer 25/04/2019 answer text <p>The Department fully understands that maintaining access to epilepsy medications is vitally important to many people in this country.</p><p>The production of medicines is complex and must meet rigorous quality and safety standards. Disruption to the medicines supply chain is rare, but can occur due to manufacturing issues, supply of raw materials or batch failures.</p><p>The Department has well established processes to monitor the medicines supply chain, and to manage and mitigate the small number of supply problems that may arise at any one time. In addition, from January this year, it became a legal requirement for pharmaceutical companies to report this information to us in a timely manner. The new requirements aim to address the ongoing concerns about medicine supply issues and to ensure that the Department has relevant information at the earliest point possible to help manage supply shortages and mitigate any potential impacts on patients.</p><p>The Department responded to concerns over medicines used in epilepsy by seeking specialist advice to develop a clinical management plan. The clinical management plan aims to ensure treatment for affected patients can be managed appropriately in the unlikely event of any disruption to supply. We communicated information about the supply issue and clinical management plan to the National Health Service and affected patients via patient groups.</p><p>We continue to work closely with industry and partners in the health system to help prevent shortages and to ensure that the risks to patients are minimised when supply issues do arise.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 245843 question first answered 25/04/2019 14:14:30 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4432 label Biography information for Patrick Grady

1122083

	registered interest
	date	18/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will respond to the request from the Epilepsy Society for an urgent review of the medicines supply chain.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	245843
	answer	answer is ministerial correction date of answer 25/04/2019 answer text <p>The Department fully understands that maintaining access to epilepsy medications is vitally important to many people in this country.</p><p>The production of medicines is complex and must meet rigorous quality and safety standards. Disruption to the medicines supply chain is rare, but can occur due to manufacturing issues, supply of raw materials or batch failures.</p><p>The Department has well established processes to monitor the medicines supply chain, and to manage and mitigate the small number of supply problems that may arise at any one time. In addition, from January this year, it became a legal requirement for pharmaceutical companies to report this information to us in a timely manner. The new requirements aim to address the ongoing concerns about medicine supply issues and to ensure that the Department has relevant information at the earliest point possible to help manage supply shortages and mitigate any potential impacts on patients.</p><p>The Department responded to concerns over medicines used in epilepsy by seeking specialist advice to develop a clinical management plan. The clinical management plan aims to ensure treatment for affected patients can be managed appropriately in the unlikely event of any disruption to supply. We communicated information about the supply issue and clinical management plan to the National Health Service and affected patients via patient groups.</p><p>We continue to work closely with industry and partners in the health system to help prevent shortages and to ensure that the risks to patients are minimised when supply issues do arise.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 245842 question first answered 25/04/2019 14:14:30 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4432 label Biography information for Patrick Grady

1176479

	registered interest
	date	05/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Radioisotopes: Imports
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps the Government is taking to ensure the continued supply of isotope species for medical (a) diagnosis and (b) treatment after the transition period.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	13021
	answer	answer is ministerial correction date of answer 10/02/2020 answer text <p>The United Kingdom has now left the European Union and entered the transition period, which will run until 31 December 2020.</p><p> </p><p>EU regulations on medicines and medical devices, including medical radioisotopes, will continue to apply to the UK throughout the transition period, during which we will negotiate a new trade agreement with the EU.</p><p> </p><p>All necessary measures are in place to ensure that civil nuclear sector can continue to operate in the UK after the end of the transition period.</p><p> </p><p>Both the EU and the UK are committed to agreeing a future partnership by the end of 2020 and are working to achieve this. It is in the interests of both the UK and the EU to agree a future partnership that keeps goods flowing, services being provided, and business being done.</p><p> </p><p> </p> answering member constituency Charnwood answering member printed Edward Argar question first answered 10/02/2020 16:57:50 answering member 4362 label Biography information for Edward Argar
	tabling member	4432 label Biography information for Patrick Grady

1192284

	registered interest
	date	01/05/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of using camostat mesylate in the treatment of patients with covid-19.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	42092
	answer	answer is ministerial correction date of answer 15/05/2020 answer text <p>There are currently no approved treatments for COVID-19 and full evaluation of the merits of any potential treatments can only be made once clinical trials involving COVID-19 patients have been completed. The United Kingdom Government is considering a wide range of potential treatments in the current UK clinical trials. Drugs representing a range of relevant modes of action including - but not limited to - serine protease inhibitors, such as camostat, are being reviewed and prioritised by a panel of experts so that the most promising are put into clinical trials first.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 15/05/2020 11:25:11 answering member 4380 label Biography information for Jo Churchill previous answer version 19579 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4432 label Biography information for Patrick Grady

1192285

	registered interest
	date	01/05/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of using therapeutic plasma in the treatment of patients with covid-19.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	42093
	answer	answer is ministerial correction date of answer 11/05/2020 answer text <p>On 25 April, the Department announced that the clinical trial REMAP-CAP was given approval to determine as part of a trial, if plasma donated by patients who have recovered from COVID-19 can help those with the virus. NHS Blood and Transplant has started to collect convalescent plasma to supply to REMAP-CAP and the first transfusion took place last week.</p><p>In parallel with the trial, NHS Blood and Transplant is scaling up a national programme for collecting plasma so the treatment can be widely rolled out if it is shown to be effective. The collection of plasma will be ramped up by mid-May to deliver up to 10,000 units of plasma to the National Health Service every week, enough to treat 5,000 COVID-19 patients per week.</p><p>Convalescent plasma has been used as an effective treatment for emerging infections in the past, and this step forward underpins the Department’s scientific approach to fighting this virus.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 11/05/2020 11:36:35 answering member 4527 label Biography information for Helen Whately previous answer version 19580 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4432 label Biography information for Patrick Grady

1192287

	registered interest
	date	01/05/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what funding his Department is providing for research into the potential merits of using therapeutic plasma in the treatment of patients with covid-19.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	42094
	answer	answer is ministerial correction date of answer 11/05/2020 answer text <p>The Department invests £1 billion per year in health research through the National Institute for Health Research (NIHR). The NIHR is prioritising clinical research activity on COVID-19 through its national prioritisation process for Urgent Public Health research. The REMAP-CAP trial is one of several studies that have been nationally prioritised. This is a platform clinical trial testing the effectiveness of multiple treatments on COVID-19 patients in intensive care. The NIHR is supporting prioritised studies such as REMAP-CAP to expedite their local set-up, management and delivery through the NIHR Clinical Research Network. As announced on 25 April, the Department is working in collaboration with NHS Blood and Transplant and the other United Kingdom blood services, Public Health England and NHS Digital to enable the testing of convalescent plasma through this trial. Details of funding for this will be made publicly available shortly.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 11/05/2020 11:24:23 answering member 4527 label Biography information for Helen Whately previous answer version 19581 answering member constituency Faversham and Mid Kent answering member printed Helen Whately answering member 4527 label Biography information for Helen Whately
	tabling member	4432 label Biography information for Patrick Grady